ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Death,Death and sudden death,Fatal outcomes,Genrl,N
1,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
1,3,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
2,1,Blood HIV RNA decreased,Virus identification and serology,Microbiology and serology investigations,Inv,N
3,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4,1,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
5,1,Hepatitis B,Hepatitis virus infections,Viral infectious disorders,Infec,N
6,1,Pharyngeal oedema,Pharyngeal disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
6,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
7,1,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
7,2,Laryngeal erythema,Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
7,3,Laryngeal oedema,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
7,4,Laryngospasm,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
7,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
7,6,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
7,7,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
7,8,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
8,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
8,2,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
8,3,Laryngeal erythema,Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
8,4,Laryngeal oedema,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
8,5,Laryngospasm,"Laryngeal spasm, oedema and obstruction",Upper respiratory tract disorders (excl infections),Resp,N
8,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
8,7,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,8,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
8,9,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
9,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
9,2,Unintended pregnancy,Unintended pregnancies,"Pregnancy, labour, delivery and postpartum conditions",Preg,N
10,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
10,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
11,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
11,2,Headache,Headaches NEC,Headaches,Nerv,N
12,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,1,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
14,1,Enuresis,Psychiatric elimination disorders,Psychiatric disorders NEC,Psych,N
15,1,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
16,1,Fibrosis,Fibrosis NEC,Tissue disorders NEC,Genrl,N
16,2,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
16,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
16,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
17,1,Abortion induced,Induced abortions,Obstetric and gynaecological therapeutic procedures,Surg,N
17,2,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
18,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
19,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
19,2,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
20,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
20,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
21,1,Lactic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
22,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
23,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
24,1,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
26,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
27,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
28,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
29,1,Viral load increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
30,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
31,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
32,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
32,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
33,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
33,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
34,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
34,2,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
34,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
35,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
36,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
37,1,Gastrointestinal tube insertion,Gastrointestinal therapeutic procedures NEC,Gastrointestinal therapeutic procedures,Surg,N
38,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
39,1,Hepatitis B DNA increased,Virus identification and serology,Microbiology and serology investigations,Inv,N
40,1,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
41,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
41,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
42,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
42,2,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
42,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
43,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
43,2,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
44,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
44,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
45,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
45,2,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
46,1,Progressive multifocal leukoencephalopathy,Polyomavirus infections,Viral infectious disorders,Infec,N
47,1,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
48,1,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
48,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
49,1,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
49,2,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
50,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
50,2,Optic disc hyperaemia,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
50,3,Retinal depigmentation,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
50,4,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
50,5,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
50,6,Visual field defect,Visual field disorders,Vision disorders,Eye,N
51,1,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
52,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
52,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
52,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
53,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
54,1,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
54,2,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
54,3,Hyperlactacidaemia,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
54,4,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
54,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
54,6,Liver abscess,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,Y
54,7,Lung consolidation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
54,8,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
54,9,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
55,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
55,2,Optic disc hyperaemia,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
55,3,Retinal depigmentation,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
55,4,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
55,5,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
55,6,Visual field defect,Visual field disorders,Vision disorders,Eye,N
56,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
56,2,Glomerulonephritis membranous,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
57,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
58,1,Deafness,Hearing losses,Hearing disorders,Ear,N
59,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
59,2,Glomerulonephritis membranous,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
60,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
60,2,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
61,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
62,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
63,1,Palliative care,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
64,1,Pregnancy,"Normal pregnancy, labour and delivery","Pregnancy, labour, delivery and postpartum conditions",Preg,N
65,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
65,2,Pathogen resistance,Infections NEC,Infections - pathogen unspecified,Infec,N
66,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
